Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity

Yusong Wang, Mozhi Wang, Keda Yu, Shouping Xu, Pengfei Qiu, Zhidong Lyu, Mingke Cui, Qiang Zhang and Yingying Xu
Cancer Biology & Medicine March 2023, 20 (3) 218-228; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0513
Yusong Wang
1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mozhi Wang
1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keda Yu
2Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shouping Xu
3Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pengfei Qiu
4Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhidong Lyu
5Breast Center, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingke Cui
6Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110801, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiang Zhang
6Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110801, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qiang Zhang
  • For correspondence: [email protected] [email protected]
Yingying Xu
1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yingying Xu
  • For correspondence: [email protected] [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Siegel RL,
    2. Miller KD,
    3. Fuchs HE,
    4. Jemal A.
    Cancer statistics, 2022. CA Cancer J Clin. 2022; 72: 7–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Geoerger B,
    2. Kang HJ,
    3. Yalon-Oren M,
    4. Marshall LV,
    5. Vezina C,
    6. Pappo A, et al.
    Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020; 21: 121–33.
    OpenUrlCrossRefPubMed
  3. 3.
    1. Goldberg SB,
    2. Schalper KA,
    3. Gettinger SN,
    4. Mahajan A,
    5. Herbst RS,
    6. Chiang AC, et al.
    Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020; 21: 655–63.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Balar AV,
    2. Galsky MD,
    3. Rosenberg JE,
    4. Powles T,
    5. Petrylak DP,
    6. Bellmunt J, et al.
    Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389: 67–76.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mittendorf EA,
    2. Zhang H,
    3. Barrios CH,
    4. Saji S,
    5. Jung KH,
    6. Hegg R, et al.
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396: 1090–100.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Schmid P,
    2. Rugo HS,
    3. Adams S,
    4. Schneeweiss A,
    5. Barrios CH,
    6. Iwata H, et al.
    Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21: 44–59.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Adams S,
    2. Gray RJ,
    3. Demaria S,
    4. Goldstein L,
    5. Perez EA,
    6. Shulman LN, et al.
    Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32: 2959–66.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Denkert C,
    2. von Minckwitz G,
    3. Darb-Esfahani S,
    4. Lederer B,
    5. Heppner BI,
    6. Weber KE, et al.
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19: 40–50.
    OpenUrlPubMed
  9. 9.↵
    1. Wang M,
    2. Pang Z,
    3. Wang Y,
    4. Cui M,
    5. Yao L,
    6. Li S, et al.
    An immune model to predict prognosis of breast cancer patients receiving neoadjuvant chemotherapy based on support vector machine. Front Oncol. 2021; 11: 651809.
  10. 10.↵
    1. Cortazar P,
    2. Zhang L,
    3. Untch M,
    4. Mehta K,
    5. Costantino JP,
    6. Wolmark N, et al.
    Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (Lond, Engl). 2014; 384: 164–72.
    OpenUrl
  11. 11.↵
    1. Jakobsen JC,
    2. Gluud C,
    3. Wetterslev J,
    4. Winkel P.
    When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017; 17: 162.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Mellenbergh GJ,
    2. Adèr HJ
    1. Lodder P.
    To impute or not impute: that’s the question. In: Mellenbergh GJ, Adèr HJ, eds. Advising on research methods: selected topics 2013. Huizen, The Netherlands: Johannes van Kessel Publishing; 2014.
  13. 13.↵
    1. Schmitt P,
    2. Mandel J,
    3. Guedj M.
    A comparison of six methods for missing data imputation. J Biomet Biostat. 2015; 6: 224.000.
  14. 14.↵
    1. Torgo L.
    Data mining with R learning with case studies. 2nd ed. Chapman and Hall/CRC; 2016.
  15. 15.↵
    1. Were K,
    2. Bui DT,
    3. Dick ØB,
    4. Singh BR.
    A comparative assessment of support vector regression, artificial neural networks, and random forests for predicting and mapping soil organic carbon stocks across an Afromontane landscape. Ecol Indic. 2015; 52: 394–403.
    OpenUrl
  16. 16.↵
    1. Kuhn M,
    2. Wing J,
    3. Weston S,
    4. Williams A,
    5. Keefer C,
    6. Engelhardt A, et al.
    Caret: Classification and Regression Training; 2016. https://CRAN.R-project.org/package=caret.
  17. 17.↵
    1. Liaw A,
    2. Wiener M.
    Classification and regression by randomForest. R News. 2002; 2: 18–22.
    OpenUrlCrossRef
  18. 18.↵
    1. Robin X,
    2. Turck N,
    3. Hainard A,
    4. Tiberti N,
    5. Lisacek F,
    6. Sanchez JC, et al.
    pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12: 77.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Harrell FE Jr..
    Regression modeling strategies. 2022.
  20. 20.↵
    1. Sigal MJ,
    2. Chalmers RP.
    Play it again: teaching statistics with Monte Carlo simulation. J Stat Educ. 2016; 24: 136–56.
    OpenUrlCrossRef
  21. 21.↵
    1. Batista GEAPA,
    2. Prati RC,
    3. Monard MC.
    A study of the behavior of several methods for balancing machine learning training data. SIGKDD Explor Newsl. 2004; 6: 20–9.
    OpenUrl
  22. 22.↵
    1. Fang F,
    2. Wang W,
    3. Chen M,
    4. Tian Z,
    5. Xiao W.
    Technical advances in NK cell-based cellular immunotherapy. Cancer Biol Med. 2019; 16: 647–54.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Myers JA,
    2. Miller JS.
    Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021; 18: 85–100.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Norton L.
    Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin Oncol. 1997; 24: S11-2–S11-12.
    OpenUrlPubMed
  25. 25.↵
    1. Muntasell A,
    2. Rojo F,
    3. Servitja S,
    4. Rubio-Perez C,
    5. Cabo M,
    6. Tamborero D, et al.
    NK cell infiltrates and HLA class I expression in primary HER2(+) breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res. 2019; 25: 1535–5.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Chen DS,
    2. Mellman I.
    Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39: 1–10.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Schmid P,
    2. Cortes J,
    3. Pusztai L,
    4. McArthur H,
    5. Kümmel S,
    6. Bergh J, et al.
    Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382: 810–21.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Xie G,
    2. Dong H,
    3. Liang Y,
    4. Ham JD,
    5. Rizwan R,
    6. Chen J.
    CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59: 102975.
  29. 29.↵
    1. Chan IS,
    2. Knútsdóttir H,
    3. Ramakrishnan G,
    4. Padmanaban V,
    5. Warrier M,
    6. Ramirez JC, et al.
    Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020; 219: e202001134.
  30. 30.↵
    1. Yu M,
    2. Pan H,
    3. Che N,
    4. Li L,
    5. Wang C,
    6. Wang Y, et al.
    Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells. Cell Mol Immunol. 2021; 18: 2153–64.
    OpenUrl
  31. 31.↵
    1. Slattery K,
    2. Woods E,
    3. Zaiatz-Bittencourt V,
    4. Marks S,
    5. Chew S,
    6. Conroy M, et al.
    TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer. J Immunother Cancer. 2021; 9: e002044.
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 20 (3)
Cancer Biology & Medicine
Vol. 20, Issue 3
15 Mar 2023
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity
Yusong Wang, Mozhi Wang, Keda Yu, Shouping Xu, Pengfei Qiu, Zhidong Lyu, Mingke Cui, Qiang Zhang, Yingying Xu
Cancer Biology & Medicine Mar 2023, 20 (3) 218-228; DOI: 10.20892/j.issn.2095-3941.2022.0513

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity
Yusong Wang, Mozhi Wang, Keda Yu, Shouping Xu, Pengfei Qiu, Zhidong Lyu, Mingke Cui, Qiang Zhang, Yingying Xu
Cancer Biology & Medicine Mar 2023, 20 (3) 218-228; DOI: 10.20892/j.issn.2095-3941.2022.0513
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Supporting Information
    • Conflict of interest statement
    • Author contributions
    • Acknowledgements
    • Appendix
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect: a multistage metabolomic profiling and Mendelian randomization study
  • Nuclear PHGDH regulates macrophage polarization through transcriptional repression of GLUD1 and GLS2 in breast cancer
  • Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity
Show more Original Article

Similar Articles

Keywords

  • Breast cancer
  • neoadjuvant therapy
  • peripheral blood lymphocytes
  • machine learning
  • prediction model

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2025 Cancer Biology & Medicine

Powered by HighWire